In vitro evaluation of P-glycoprotein functions in human neuroblastoma cell lines

Main Article Content

Krai Daowtak
Suchart Kothan
Suhaida Doloh
Wiyada Dankai
Chatchanok Udomtanakunchai

Abstract

Background: Neuroblastoma (NB) remains one of the most puzzling of paediatric cancers in which most patients develop progressive disease that is refractory to chemotherapy. Effective treatment is hampered by drug resistance related to the expression of multidrug-resistant proteins belonging to the ATP-binding cassette transporters family, especially P-glycoprotein (P-gp). Most previous studies focused on molecular evidence of P-gp expression, however, functional studies of P-gp efflux have not clearly demonstrated.


Objectives: The aim of this study was to determine whether human neuroblastoma cell lines (SH-SY5Y and SK-N-SH) express the functionally active P-gp efflux pump.


Materials and methods: Functional studies on P-gp–mediated pumping were performed using pirarubicin, a P-gp substrate, with verapamil, a multidrug resistance inhibitor, and analyzed by a spectrofluorometer. To confirm the gene expression, reverse transcription polymerase chain reaction (RT-PCR) was performed with specific primers for human multidrug resistance 1 (MDR1).


Results: MDR1 expression was observed in neuroblastoma cell line (SH-SY5Y) in the same degree of expression as in the sensitive K562 cell line, a negative P-gp model. Kinetic analysis showed that there was no difference in drug accumulation in the presence or absence of verapamil, indicating that no function of P-gp influenced the accumulation of pirarubicin (PIRA) in both human neuroblastoma cell lines. Combination treatment of verapamil and PIRA was also not found to increase the sensitivity of PIRA.


Conclusion: This study suggests that the existence of P-gp in neuroblastoma cell lines is not significant function.

Article Details

How to Cite
Daowtak, K., Kothan, S., Doloh, S., Dankai, W., & Udomtanakunchai, C. (2018). In vitro evaluation of P-glycoprotein functions in human neuroblastoma cell lines. Journal of Associated Medical Sciences, 51(2), 72–80. Retrieved from https://he01.tci-thaijo.org/index.php/bulletinAMS/article/view/104482
Section
Research Articles

References

[1] Fletcher JI, Williams RT, Henderson MJ, Norris MD, Haber M. ABC transporters as mediators of drug resistance and contributors to cancer cell biology. Drug Resist Updat. 2016; 26: 1-9.

[2] Davidoff AM. Neuroblastoma. Seminars in Pediatric Surgery. 2012; 21(1): 2-14.

[3] Piskareva O, Harvey H, Nolan J, Conlon R, Alcock L, Buckley P, et al. The development of cisplatin resistance in neuroblastoma is accompanied by epithelial to mesenchymal transition in vitro. Cancer Letters. 2015; 364(2): 142-55.

[4] Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006; 5(3): 219-34.

[5] Nagaraja AK, Creighton CJ, Yu Z, Zhu H, Gunaratne PH, Reid JG, et al. A Link between mir-100 and FRAP1/mTOR in Clear Cell Ovarian Cancer. Molecular Endocrinology. 2010; 24(2): 447-63.

[6] Muller PAJ, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Karim S, et al. Mutant p53 Drives Invasion by Promoting Integrin Recycling. Cell. 2009; 139(7): 1327-41.

[7] Ghavami S, Hashemi M, Ande SR, Yeganeh B, Xiao W, Eshraghi M, et al. Apoptosis and cancer: mutations within caspase genes. Journal of Medical Genetics. 2009; 46(8): 497-510.

[8] Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer. 2002; 2(4): 277-88.

[9] Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer and Metastasis Reviews. 2007; 26(2): 225-39.

[10] Vaupel P, Mayer A. Hypoxia and anemia: effects on tumor biology and treatment resistance. Transfusion Clinique et Biologique. 2005; 12(1): 5-10.

[11] Buhagiar A, Ayers D. Chemoresistance, Cancer Stem Cells, and miRNA Influences: The Case for Neuroblastoma. Analytical Cellular Pathology (Amsterdam). 2015; 2015: 150634.

[12] Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002; 2(1): 48-58.

[13] Davidson AL, Dassa E, Orelle C, Chen J. Structure, Function, and Evolution of Bacterial ATP-Binding Cassette Systems. Microbiol Mol Biol Rev: MMBR. 2008;72(2):317-64.

[14] Marin JJG, Monte MJ, Blazquez AG, Macias RIR, Serrano MA, Briz O. The role of reduced intracellular concentrations of active drugs in the lack of response to anticancer chemotherapy. Acta Pharmacologica Sinica. 2014; 35(1): 1-10.

[15] Yagüe E, Armesilla AL, Harrison G, Elliott J, Sardini A, Higgins CF, et al. P-glycoprotein (MDR1) Expression in Leukemic Cells Is Regulated at Two Distinct Steps, mRNA Stabilization and Translational Initiation. J Biol Chem. 2003; 278(12): 10344-52.

[16] Storch CH, Theile D, Lindenmaier H, Haefeli WE, Weiss J. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochemical Pharmacology. 2007; 73(10): 1573-81.

[17] Bousquet L, Pruvost A, Guyot A-C, Farinotti R, Mabondzo A. Combination of Tenofovir and Emtricitabine plus Efavirenz: In Vitro Modulation of ABC Transporter and Intracellular Drug Accumulation. Antimicrobial Agents and Chemotherapy. 2009; 53(3): 896-902.

[18] Weiss J, Herzog M, ouml, nig S, Storch CH, Ketabi-Kiyanvash N, et al. Induction of Multiple Drug Transporters by Efavirenz. Journal of Pharmacological Sciences. 2009; 109(2): 242-50.

[19] Burhenne J, Matthée A-K, Pasáková I, Röder C, Heinrich T, Haefeli WE, et al. No Evidence for Induction of ABC Transporters in Peripheral Blood Mononuclear Cells in Humans after 14 Days of Efavirenz Treatment. Antimicrobial Agents and Chemotherapy. 2010; 54(10): 4185-91.

[20] Janneh O, Chandler B, Hartkoorn R, Kwan WS, Jenkinson C, Evans S, et al. Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes. Journal of Antimicrobial Chemotherapy. 2009; 64(5): 1002-7.

[21] Tarasiuk J, Frézard F, Garnier-Suillerot A, Gattegno L. Anthracycline incorporation in human lymphocytes. Kinetics of uptake and nuclear concentration. Biochim Biophys Acta. 1989; 1013(2): 109-17.

[22] Frezard F, Garnier-Suillerot A. Comparison of the membrane transport of anthracycline derivatives in drug-resistant and drug-sensitive K562 cells. European Journal of Biochemistry. 1991; 196(2): 483-91.

[23] Loetchutinat C, Heywang C, Priebe W, Garnier-Suillerot A. The absence of stereoselective P-glycoprotein- and multidrug resistance-associated protein-mediated transport of daunorubicin. Biochemical Pharmacology. 2001; 62(5): 561-7.

[24] Mankhetkorn S, Dubru F, Hesschenbrouck J, Fiallo M, Garnier-Suillerot A. Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells. Molecular Pharmacology. 1996; 49(3): 532.

[25] Lozzio CB, Lozzio BB. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood. 1975; 45(3): 321-34.

[26] Tsuruo T, Iida-Saito H, Kawabata H, Oh-hara T, Hamada H, Utakoji T. Characteristics of resistance to adriamycin in human myelogenous leukemia K562 resistant to adriamycin and in isolated clones. Japanese journal of cancer research: Gann. 1986; 77(7): 682-92.

[27] Pereira E, Garnier-Suillerot A. Correlation between the short-term measurements of drug accumulation in living cells and the long-term growth inhibition. Biochemical Pharmacology. 1994; 47(10): 1851-7.

[28] Beck WT, Cirtain MC, Look AT, Ashmun RA. Reversal of Vinca Alkaloid Resistance but not Multiple Drug Resistance in Human Leukemic Cells by Verapamil. Cancer Research. 1986; 46(2): 778-84.

[29] Safa AR. Photoaffinity labeling of the multidrug-resistance-related P-glycoprotein with photoactive analogs of verapamil. Proceedings of the National Academy of Sciences of the United States of America. 1988; 85(19): 7187-91.

[30] Huet S, Robert J. The reversal of doxorubicin resistance by verapamil is not due to an effect on calcium channels. International Journal of Cancer. 1988; 41(2): 283-6.

[31] Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Research. 1981; 41(5): 1967.

[32] Peetla C, Vijayaraghavalu S, Labhasetwar V. Biophysics of cell membrane lipids in cancer drug resistance: Implications for drug transport and drug delivery with nanoparticles. Adv Drug Deliv Rev. 2013; 65(13): 1686-98.

[33] Seebacher NA, Lane DJR, Jansson PJ, Richardson DR. Glucose Modulation Induces Lysosome Formation and Increases Lysosomotropic Drug Sequestration via the P-Glycoprotein Drug Transporter. J Biol Chem. 2016; 291(8): 3796-820.

[34] Milane L, Duan Z, Amiji M. Role of hypoxia and glycolysis in the development of multi-drug resistance in human tumor cells and the establishment of an orthotopic multi-drug resistant tumor model in nude mice using hypoxic pre-conditioning. Cancer Cell International. 2011; 11:3.

[35] Hembruff SL, Laberge ML, Villeneuve DJ, Guo B, Veitch Z, Cecchetto M, et al. Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance. BMC Cancer. 2008; 8: 318.

[36 Bates SE, Mickley LA, Chen YN, Richert N, Rudick J, Biedler JL, et al. Expression of a drug resistance gene in human neuroblastoma cell lines: modulation by retinoic acid-induced differentiation. Molecular and Cellular Biology. 1989; 9(10): 4337-44.

[37] Haber M, Smith J, Bordow SB, Flemming C, Cohn SL, London WB, et al. Association of High-Level MRP1 Expression With Poor Clinical Outcome in a Large Prospective Study of Primary Neuroblastoma. Journal of Clinical Oncology. 2006; 24(10): 1546-53.

[38] Dalzell AM, Mistry P, Wright J, Williams FM, Brown CDA. Characterization of multidrug transporter-mediated efflux of avermectins in human and mouse neuroblastoma cell lines. Toxicology Letters. 2015; 235(3): 189-98.

[39] Shipley MM, Mangold CA, Szpara ML. Differentiation of the SH-SY5Y Human Neuroblastoma Cell Line. Journal of visualized experiments: JoVE 2016(108): e53193.

[40] Meesungnoen J, Jay-Gerin JP, S. M. Relation between MDR1 mRNA levels, resistance factor, and the efficiency of P-glycoprotein-mediated efflux of pirarubicin in multidrug-resistant K562 sublines. Can J Physiol Pharmacol. 2002; 80(11): 1054-63.

[41] Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 1976; 455(1): 152-62.

[42] Beck WT, Mueller TJ, Tanzer LR. Altered Surface Membrane Glycoproteins in Vinca Alkaloid resistant Human Leukemic Lymphoblasts. Cancer Research. 1979; 39(6 Part 1): 2070.

[43] Sieczkowski E, Lehner C, Ambros PF, Hohenegger M. Double impact on p-glycoprotein by statins enhances doxorubicin cytotoxicity in human neuroblastoma cells. International Journal of Cancer. 2010; 126(9): 2025-35.